Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
17.04.25
/
50%
€6.75
Target price
17.04.26
€12.32
Performance (%)
-11.85%
Price
18.12.25
€5.85
Summary
This prediction is currently active. The price of Myriad Genetics has decreased since the start of the prediction. Compared to the start price this results in a performance of -11.85%. This prediction currently runs until 17.04.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Myriad Genetics | -2.500% | -2.500% |
| iShares Core DAX® | -0.793% | 4.201% |
| iShares Nasdaq 100 | -2.376% | 0.857% |
| iShares Nikkei 225® | -2.701% | -0.147% |
| iShares S&P 500 | -1.689% | 1.244% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $14.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat